Biogen's Busy Pipeline: Continued Confusion On BAN2401, But Other Irons In The Fire

Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.

The last full week of October was action-packed for Biogen Inc., with updated Phase II data for the Alzheimer's drug BAN2401 and progress for a number of other neuroscience assets in the pipeline, but also two mid-stage failures – vixotrigine in sciatica and dapirolizumab pegol in lupus.

The pipeline update comes at a time of concern about coming competition for the company's rare disease drug Spinraza and...

More from Archive

More from Scrip